Pharmaceuticals, Biotechnology and Life Sciences
Roche’s randomised phase III ALEX study showed that Alecensa (alectinib) as an initial (first-line) treatment significantly reduced the risk of disease worsening or death (progression-free survival, PFS) compared to crizotinib in people with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Akers Biosciences, a developer of rapid health information technologies, has reported its financial results for the fiscal year ended December 31, 2016.
Johnson & Johnson’s company Codman Neuro has acquired Neuravi Limited, a company dedicated to advancing neurovascular therapies and improving clinical outcomes for acute ischemic stroke patients.
The European Medicines Agency has had expressions of interest to host the London-based regulator from 21 of the 27 countries that will form the European Union once Britain leaves, revealing rivalry from Amsterdam to Zagreb for a prized institution.
Akers Biosciences, a developer of rapid health information technologies, has begun marketing its rapid test for heparin-induced thrombocytopenia (“HIT”) to the large number of hospital facilities in Puerto Rico as an extension of the company’s strategy to accelerate U.S. sales of its flagship product.
After receiving and analyzing legally binding transaction offers from two consortia for a public tender offer for all outstanding shares, Stada’s Executive and Supervisory Board has reached the conclusion to support the bid by Bain Capital and Cinven.
Probiodrug, a Germany-based biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer’s disease (AD) and other neurodegenerative disorders, has reported that Last Patient’s Last Visit (LPLV) occurred on 05 April 2017 in the currently running Phase 2a SAPHIR study investigating the QC-inhibitor PQ912 in patients with early AD.
e-Therapeutics, the drug discovery company, announced Thursday that Dr. Raymond Barlow has assumed his position as Chief Executive Officer.
PureTech Health’s subsidiary Akili announced results from a project EVO pilot study demonstrating improved cognitive control in children with sensory processing dysfunction and attentional deficits.
NHS England is now inviting for the 2017 Clinical Fellowship Scheme for practising pharmacists.